Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Darapladib Poised To Become Latest Cardiovascular Outcomes Casualty

This article was originally published in The Pink Sheet Daily

Executive Summary

Company announces that Lp-PLA2 inhibitor darapladib fails Phase III STABILIITY outcomes study, the latest in a string of pharma CV failures.

You may also be interested in...



Surprise! It’s A Phase III Failure

When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.

GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger

GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.

Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback

GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it puts more pressure on the company to deliver on its respiratory launches.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel